
Phase 1 (Ph1) Clinical and Pharmacodynamic (PD) Study of a Pure MEK Inhibitor (MEKi), RO4987655, in RAS-BRAF Mutant Patient Populations with Advanced or Metastatic Solid Tumors
Proffered Paper Session
November 08, 2012 | Length: 17:52 min
Further Lectures


Innate and adaptive immunity regulated within the tumor microenvironment
Microenvironment

Targeting Tumour-Stroma Interaction for Prevention of Metastasis
Microenvironment

Prostate Specific Membrane Antigen Antibody Drug Conjugate (PSMA ADC): a Phase 1 Trial in Castration-Resistant Metastatic Prostate Cancer (mCRPC)
Proffered Paper Session
Infos
Congress: | 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
---|---|
Presenter: | R. Bahleda |
Category: | Cancer; Clinical Trials; Oncogenes; RAS; metastasis; |